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Refractory anaphylaxis (unresponsive to treatment with at least two doses of minimum
300 µg adrenaline) is a rare and often fatal hypersensitivity reaction. Comprehensive
data on its definition, prevalence, and risk factors are missing. Using the data from
the European Anaphylaxis Registry (11,596 cases in total) we identified refractory
anaphylaxis cases (n = 42) and analyzed these in comparison to a control group of
severe anaphylaxis cases (n = 4,820). The data show that drugs more frequently elicited
refractory anaphylaxis (50% of cases, p< 0.0001) compared to other severe anaphylaxis
cases (19.7%). Cases elicited by insects (n= 8) were more often due to bees than wasps
in refractory cases (62.5 vs. 19.4%, p = 0.009). The refractory cases occurred mostly
in a perioperative setting (45.2 vs. 9.05, p < 0.0001). Intramuscular adrenaline (as a
first line therapy) was administered in 16.7% of refractory cases, whereas in 83.3% of
cases it was applied intravenously (significantly more often than in severe anaphylaxis
cases: 12.3%, p < 0.0001). Second line treatment options (e.g., vasopression with
dopamine, methylene blue, glucagon) were not used at all for the treatment of refractory
cases. The mortality rate in refractory anaphylaxis was significantly higher (26.2%)
than in severe cases (0.353%, p < 0.0001). Refractory anaphylaxis is associated with
drug-induced anaphylaxis in particular if allergens are given intravenously. Although
physicians frequently use adrenaline in cases of perioperative anaphylaxis, not all patients
are responding to treatment. Whether a delay in recognition of anaphylaxis is responsible
for the refractory case or whether these cases are due to an overflow with mast cell
activating substances—requires further studies. Reasons for the low use of second-line
medication (i.e., methylene blue or dopamine) in refractory cases are unknown, but their
use might improve the outcome of severe refractory anaphylaxis cases.
Keywords: anaphylaxis, adrenaline (epinephrine), beta-blockers, insect venom allergy, drug allergic reactions,
vasoconstriction, refractory
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INTRODUCTION
Anaphylaxis is a non-homogeneous clinical diagnosis, depending
on various triggering and augmenting factors (1). This variability
introduces a wide range of possible reaction-symptom severities.
Therefore, multiple subtypes of anaphylaxis have been previously
identified (i.e., food-dependent exercise-induced anaphylaxis,
venom anaphylaxis, biphasic anaphylaxis).
The mainstay of anaphylaxis management is the
intramuscular dose of adrenaline (2), but in the most severe
cases of anaphylaxis, it might be insufficient to restore a stable
patient status. Refractory anaphylaxis (although the established
definition is lacking) might be defined as anaphylaxis meeting the
criteria by NIAID/FAAN (3) which, after the treatment with at
least two doses of minimum 300 µg adrenaline, does not achieve
normalization of the clinical symptoms in a given individual.
Common elicitors and symptoms of refractory anaphylaxis, as
well as the therapeutic strategy for the most severe cases, differ
from the usual reactions (4) and call for specific research and
targeted guideline development for refractory anaphylaxis cases.
We aimed to distinguish the prevalence of refractory
anaphylaxis among anaphylaxis cases and to describe symptoms
and factors which may increase the risk of a refractory
anaphylaxis episode.
METHODS
The European Anaphylaxis Registry [described in detail
elsewhere (5)] provided data for this analysis (status from March
2018). We selected cases where patients received at least two
doses of adrenaline and failed to recover adequately and assigned
them to the “refractory anaphylaxis group.” The flowchart in
Figure 1 represents the detailed case-selection process.
The final database consisted of 42 cases of refractory
anaphylaxis from 7 countries: Germany: 19, Switzerland: 11,
France: 6, Austria: 2, Poland: 2, Spain: 1, Ireland: 1.We compared
these to a group of severe, non-refractory cases of anaphylaxis.
Severe reactions were identified based on the definition by
NIAID/FAAN (3) and presented with significant hypoxia,
hypotension, confusion, collapse and loss of consciousness, or
incontinence. We compared the frequency of various elicitors,
symptoms, and factors known to increase the risk of severe
anaphylaxis (6) in both groups as well as their management.
We performed a statistical analysis in the R Statistical Package
(7). A simple comparison of categorical variables was performed
using Fisher’s exact test; continuous variables were analyzed using
the Mann-Whitney U-test. We defined statistical significance as
α = 0.05. Data, along with the analysis script, can be accessed
at www.github.com/wolass/RefractoryAnaOrg.
RESULTS
Refractory Anaphylaxis Accounts for Less
Than 0.5% of Severe Anaphylaxis Cases in
the Register
The European Anaphylaxis Registry captured 42 cases of
refractory anaphylaxis and 4,820 severe, non-refractory
anaphylaxis. The frequency of refractory anaphylaxis was
0.37% of all anaphylaxis cases reported in the registry.
Each year ∼1% (0.853% ± 0.765%) of severe anaphylactic
episodes are refractory to treatment with adrenaline.
When considering patients who experienced anaphylaxis
in a perioperative setting or a medical facility, nearly
3.72% patients present with reactions that do not respond
to adrenaline vs. 0.448% in non-medical setting (9.3
times more).
Increased Frequency of Previous
Reactions in Patients With Refractory
Anaphylaxis
The mean age at the reaction was 41.4 ± 20.8 years, which
did not differ from severe, non-refractory cases, p = 0.897).
The percentage of males within the refractory anaphylaxis group
was 50%. More patients suffered from a concomitant malignant
disease in the refractory anaphylaxis group. Most strikingly,
patients with refractory reactions more often had a previous
anaphylactic reaction in their medical history (p = 0.0336).
Baseline tryptase levels were significantly higher in the refractory
anaphylaxis group as 7 refractory patients (16.7%) had tryptase
level above 11.5 µg/L (vs. 7.8%). The demographic summary of
refractory cases is shown in Table 1.
Drugs Are the Most Frequent Elicitors of
Refractory Anaphylaxis
Refractory anaphylaxis was most commonly elicited by drugs
(significantly more often than in severe, non-refractory cases),
followed by food and insects (Table 2). The most common drugs
eliciting anaphylaxis refractory to adrenaline were antibiotics
(19%) and radiocontrast media (RCM, 7.14%). Patients with
refractory anaphylaxis more frequently experienced the reaction
while undergoing a medical procedure (54.8% vs. 12.3 in severe,
non-refractory cases, p< 0.0001).
Thirty three percent of food elicited refractory cases had
a previously confirmed diagnosis of food allergy. Insect-
venom and food allergens most frequently elicited severe
cases of anaphylaxis. Refractory anaphylaxis cases were more
often elicited by bees than severe, non-refractory cases,
p= 0.0092 (Table 3).
Refractory Anaphylaxis Is Life-Threatening
Milder anaphylaxis symptoms (i.e., pruritus, gastrointestinal
symptoms, vertigo, chest, and throat tightness) were significantly
less present in refractory anaphylaxis cases, whereas respiratory
and cardiac arrest, as well as inspiratory and expiratory
distress, and death were more often associated with the
refractory anaphylaxis cases. Table 4 summarizes the most
prominent differences in anaphylaxis symptoms among both
groups. Fatal reactions frequently occurred 30–120min after
allergen exposure and were highly associated with refractory
cases (26.2% vs. only 0.353% of severe anaphylaxis cases,
p < 0.0001) In cases where patients responded to life
support, but failed to be reanimated due to post-resuscitative
complication (e.g., hypoxic brain injury), death occurred in the
next 3–8 days.
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FIGURE 1 | Flowchart illustrating the cases selection process for the final database.
Adrenaline i.v. as First-Line Treatment Was
Given Frequently in Refractory Anaphylaxis
When evaluating the therapeutic procedures, adrenaline i.v. as a
first-line treatment of anaphylaxis was significantly more often
given in refractory cases (83.3% vs. 16.7%, p < 0.0001). Median
time to the second dose of adrenaline was also shorter in
refractory cases (2 vs. 15min in non-refractory cases, p<0.0001).
Corticosteroids i.v. were the second most frequently
administered group of drugs in refractory cases (as a first and
second-line treatment), outpacing antihistaminic drugs, and
volume replacement therapy, and were significantly more often
given in refractory cases. Volume replacement therapy was given
initially in 61.9% of refractory cases and was sustained only in
19% as the therapy progressed in the hospital environment.
Second-line medication like dopamine, glucagon, and
methylene blue were not given in all refractory anaphylaxis
cases as well as in severe non-refractory ones. However, patients
with refractory anaphylaxis were more frequently admitted to
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TABLE 1 | Summary of the refractory anaphylaxis cases.
Sex Group n Age Cardiologic DM Food allergy Mastocytosis Malignancy Atopic dermatitis Tryptase [median]
Female Refractory 22 40.0 31.82 9.09 13.64 9.09 0.00 18.18 5.22
Male Refractory 20 43.0 30.00 15.00 5.00 5.00 15.00 5.00 7.43
Female Severe 2421 43.4 20.57 2.27 5.37 2.56 2.19 6.73 4.30
Male Severe 2399 40.2 22.89 3.58 5.84 2.54 2.08 6.25 4.72
p-value 0.78 0.9 0.19 0.07 1.00 0.10 0.07 0.20 0.01
Age is represented by a mean value, other variables as fractions [%]. DM, diabetes mellitus, p-value is derived from a Mann-Whitney U-test or a Chi2 test for interval and categorical
variables, respectively. Refractory group was compared to severe anaphylaxis cases without differentiating into male and female subgroups.
TABLE 2 | Summary of elicitors in the refractory anaphylaxis cases and severe, non-refractory anaphylaxis cases as a control.
Elicitor n % % severe ANA Perioperative [n] Food allergy [n] Age Male [%] p
Food 9 21.4 24.1 0 3 17.4 55.6 0.8560
Drugs 21 50.0 19.7 19 0 48.8 42.9 0.0001
Insects 8 19.0 48.1 0 0 46.5 62.5 0.0001
Other 2 4.8 3.0 0 1 38.0 0.0 0.3610
Unknown 2 4.8 5.1 0 0 55.5 50.0 0.0001
ANA, anaphylaxis, age is represented as a mean, p-value derived from the Fisher’s exact test.
TABLE 3 | Comparison of the specific elicitors from each elicitor-group between
the refractory anaphylaxis cases and severe anaphylaxis cases as a control.
Elicitor Severe ANA [%] Refractory ANA [%] p-value
Antibiotics 6.140 19.00 0.0040
X-ray medium 0.954 7.14 0.0080
Muscle relaxant 0.456 4.76 0.0180
Legumes 4.020 7.14 0.2410
Bee venom 9.320 11.90 0.5890
Yellow-jacket venom 33.300 4.76 0.0001
ANA, anaphylaxis, p-value derived from the Fisher’s exact test.
the hospital (85.7%) and treated at the ICUs (78.6%). Table 5
illustrates the therapy of refractory anaphylaxis cases.
Cofactors of Refractory Anaphylaxis
Patients with refractory anaphylaxis more often had concomitant
asthma and malignant diseases in their medical history. Also,
other unspecified concomitant conditions were significantly
more often reported in refractory cases. Concomitant cardiologic
conditions, diabetes, and mastocytosis were similarly frequent in
both groups.
Patients with refractory anaphylaxis more often reported
concomitant intake of proton pump inhibitors (PPI) and
acetylsalicilic acid (ASA) compared with patients with severe
non-refractory anaphylaxis. Other (not specified) medications
were also more frequent in refractory cases. In 6 cases of
refractory anaphylaxis (14.3%) patients reported receiving beta-
blockers as a concomitant medication, but none of these patients
received a glucagon infusion.
TABLE 4 | Summary of the symptoms in the refractory anaphylaxis cases and
severe, non-refractory anaphylaxis cases as a control.
Symptom Severe ANA [%] Refractory ANA [%] p-value
Pruritus 45.40 23.80 0.0050
Skin symptoms 44.80 26.20 0.0190
Respiratory symptoms 62.10 81.00 0.0150
Respiratory arrest 3.03 28.60 0.0001
Chest tightness 8.90 2.38 0.1760
Throat tightness 14.60 7.14 0.2680
Expiratory distress 5.08 26.20 0.0001
Inspiratory stridor 5.31 19.00 0.0020
Loss of consciousness 31.90 40.50 0.2470
Cardiac arrhythmia 3.30 11.90 0.0130
Cardiac arrest 3.07 42.90 0.0001
Vertigo 38.70 14.30 0.0001
Death 0.35 26.20 0.0001
ANA, anaphylaxis, p-value derived from the Fisher’s exact test.
The intensity of physical exercise exceeding the reaction
was indifferent between groups, however psychological burden
(defined as a stressful event preceding the reaction, rated by the
physician) was reported three times more frequently in refractory
cases (see Table 6).
DISCUSSION
Frequency of Refractory Anaphylaxis and
Patients at Risk
Our findings suggest that around 1 in 100 severe anaphylaxis
patients will not respond to the standard therapy with adrenaline,
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TABLE 5 | Summary of therapeutic measures in the refractory anaphylaxis cases
and severe, non-refractory anaphylaxis cases as a control.
Therapy Severe ANA [%] Refractory ANA [%] p-value
Adrenaline i.m. 8.38 16.70 0.0840
Adrenaline i.v. 12.30 83.30 0.0001
Adrenaline i.v. 2nd line 0.73 40.50 0.0001
Volume 20.50 61.90 0.0001
Volume, 2nd line 3.34 19.00 0.0001
Antihistaminics i.v. 40.90 64.30 0.0030
Antihistaminics i.v. 2nd line 3.84 21.40 0.0001
Corticosteroids, all routes 5.52 7.14 0.5040
Corticosteroids i.v. 48.80 73.80 0.0020
Corticosteroids i.v. 2nd line 5.37 28.60 0.0001
Beta-2-mimetics i.v. 0.66 2.38 0.2500
Beta-2-mimetics inh. 2nd line 0.75 7.14 0.0040
Theophylline i.v. 0.42 0.00 1.0000
100% oxygen 9.42 47.60 0.0001
Dopamine i.v. 0.04 0.00 1.0000
Glucagon i.v. 0.02 0.00 1.0000
Methylene blue 0.00 0.00 1.0000
Hospital admission 28.00 85.70 0.0001
Intensive care 7.55 78.60 0.0001
“2nd line” refers to the therapy performed by the professional medical emergency team
after the initial rescue procedures. ANA, anaphylaxis, p-value derived from the Fisher’s
exact test.
commonly outlined in anaphylaxis management guidelines (8).
Such cases have the highest risk of a fatal outcome, and therefore
need to be treated accordingly. Early use of adrenaline andmaybe
other second-line drugs (e.g., methylene blue and dopamine)
might increase their survival chance.
Overall, the severity of anaphylaxis and its probable transition
into a refractory episode might depend on several co-influencing
mechanisms: (1) elicitors—the type and dose of an eliciting
agent and route of exposure; (2) cofactors—the presence of other
individual and external factors which may increase the severity
of a given reaction, e.g., concomitant use of a beta-blocker; (3)
compensation—how well the affected individual can compensate
reaction symptoms, e.g., hypotension; (4) therapy—how fast and
accurately the therapeutic interventions were applied (Figure 2).
Elicitors
Drugs were the most commonly occurring elicitor, which is in
concordance with the literature and our previous findings (4).
Multiple medications with mast cell activation potential (9) given
in a perioperative setting increase the chance of a hypersensitivity
reaction and drug interactions (10). A recent study on IgE-
independent anaphylaxis showed that perioperative drugs (i.e.,
rocuronium, tubocurarine, fluoroquinolones, atracurium) might
trigger anaphylaxis by activating mast cells directly through
the MRGPRX2 receptor (11). Therefore, patients undergoing
surgical procedures and having a history of anaphylaxis should
remain under extraordinary caution.
TABLE 6 | Factors potentially increasing the risk of a severe anaphylaxis
investigated in refractory cases.
Factor Severe ANA
[%]
Refractory
ANA [%]
p-value
Concomitant asthma 12.10 29.30 0.0030
Concomitant AD 6.82 12.20 0.2000
Concomitant diabetes 5.80 13.20 0.0700
Concomitant cardiologic condition 22.80 31.70 0.1910
Concomitant infection 3.35 4.88 0.6480
History of malignant disease 3.12 10.80 0.0290
Concomitant mastocytosis 2.68 7.32 0.0990
Concomitant other disease—unspecified 15.60 36.60 0.0001
Exercise prior to reaction 28.10 21.40 0.3920
Psychological burden 6.79 26.20 0.0001
Concomitant medication 37.50 60.50 0.0060
ASA 6.13 18.40 0.0080
Beta-blockers 10.40 15.80 0.2810
PPI 5.81 20.60 0.0030
Other drugs 18.20 44.70 0.0001
Alcohol use prior to the reaction 5.51 2.63 0.7210
ANA, anaphylaxis, p-value derived from the Fisher’s exact test.
Antibiotics, although commonly triggering IgE-dependent
reactions (12), are rarely reported in the literature as the cause of
refractory anaphylaxis. RCM, on the other hand, commonly elicit
IgE-independent hypersensitivity episodes that are refractory
to adrenaline and are responsible for 1–5 deaths per 100,000
administrations (13). We previously reported RCM to be the
most frequent elicitor of refractory anaphylaxis (4). It might
be that RCM promotes complement activation (14) and thus—
unspecific activation of multiple immune cell classes (mast cells,
basophils, platelets, and neutrophils). Therefore, treatment with
adrenaline may be less effective in these reactions.
Yellow-jacket-stings elicited only a few refractory cases.
Therefore, the ratio of yellow-jacket to honey-bee venom elicited
anaphylaxis was inverted in the refractory group. Reasons for
this observation might include higher allergen exposition due to
either extended exposition to the allergen (bee’s sting remains in
the skin) or the venom volume being 10 times higher than in a
wasp sting (15).
Risk Factors
Although we have previously identified higher age and male
sex to be associated with severe anaphylaxis (6), these factors
seem to be less critical in refractory anaphylaxis cases. By
contrast, we previously associated concomitant asthma with less
severe anaphylaxis in our registry data (6). However, the present
analysis, as well as other previous data (16), suggest concomitant
asthma as a risk factor for a severe episode. Probably the control
of the asthmatic condition is essential in this context and should
be therefore evaluated in patients at risk. Moreover, it might
be possible that during a refractory episode the bronchospasm
is additionally triggered via mediators derived from basophils
and eosinophils or the vegetative nerve system what makes it
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FIGURE 2 | Visual representation of the three forces determining the severity of anaphylaxis. The natural ability of the body to compensate for the anaphylaxis
symptoms and therapeutic measures acting to restore homeostasis. Elicitors and cofactors influence the severity of a given episode synergistically.
refractory to adrenaline and results in a prolonged anaphylactic
episode. Accordingly, we observed more respiratory distress
symptoms in the refractory anaphylaxis cases.
Baseline serum tryptase (BST) levels were increased in patients
with refractory anaphylaxis, although only in 7 patients they
exceeded the threshold level of 11.5 ng/mL—what is commonly
recognized as elevated (17). BST may reflect pro-β tryptase
due to increased body mast cell content (18) or result from
alpha-tryptasemia due to multiple copies of TPSAB1 gene (19).
Irrespective of the mechanism—increased BST has been shown
to correlate with the severity of anaphylaxis (20).
The higher rate of malignancy in patients with refractory
anaphylaxis diseases might be a confounder as certain
intravenous chemotherapeutics are well known to directly
activate mast cells (e.g., taxanes) (21). On the other hand, it is
possible that patients with reported malignancies were older
(mean age of 34.6 vs. 58.3 years, p < 0.001) and therefore less
able to compensate the anaphylactic shock.
Psychological stress in temporal proximity to the reaction
might increase the severity of the reaction as we previously
reported (6). Stress induces the complement cascade activation
(22). Substance P, released during stress (23), is a known
vasodilator (24) and can activate mast cells directly (25). These
mediators may contribute to an increased mast cell response and
more severe anaphylaxis. Some published case reports indicated
stressful event as the anaphylaxis trigger (26).
Wölbling et al. indicated the role of PPI as a risk factor
for severe anaphylaxis by prolonging the exposition to an oral
allergen (preventing its degradation due to lower gastric acid
production) (27). Moreover, there are reports on PPI themselves
as elicitors of anaphylaxis (28). We observed a significantly
higher rate of PPI intake in the refractory anaphylaxis group. Its
mechanistic contribution to the increase in severity of an episode
or being responsible for its refractoriness cannot be estimated
based on this observation.
Concomitant ASA use was also associated with refractory
cases more frequently than in severe anaphylaxis. The role of
ASA on increasing the severity of anaphylaxis has previously been
implicated by increasing the intestinal absorption of allergens
(27). Nevertheless, as ASAmight be both a cofactor and elicitor of
anaphylaxis (29) and is highly correlated with another cofactor—
concomitant cardiologic conditions—it is tough to evaluate its
isolated influence on the anaphylaxis severity.
Symptom Compensation
Age is the most critical factor influencing the risk of developing
severe anaphylaxis (6). We and others have shown that
older age may correlate with the decreased ability to retain
homeostasis on increased strain (30). Patients who underwent
refractory anaphylaxis more often had perioperative reactions
and therefore, a decreased ability to compensate the reaction
symptoms with reflexive renal or cardiopulmonary response (31).
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Compensation mechanisms demonstrated in animal
models indicated that anaphylactic hypotension activates
the hypothalamic paraventricular nucleus, medullary nucleus
tractus solitarii, and rostral ventrolateral medulla, independently
of the baroreflex pathway. Further, it stimulates efferent
sympathetic nerve activity to the adrenal gland and kidney to
restore blood pressure (32).
Therapy
Physicians and surgeons often used adrenaline i.v. as first-
line therapy in refractory cases, probably because most of
them occurred in a medical setting. However, other second-
line therapeutic options were rarely used. Grabenhenrich et al.
(2) recently evaluated the epinephrine usage in anaphylaxis
patients and concluded that, even in this state of the art drug,
significant discrepancies between recommended use and actual
treatment practice exist. Similarly, US studies documented poor
adherence in patients and caregivers to anaphylaxis guidelines
recommending more than one adrenaline autoinjector available
at all times (33). Therefore, more effort needs to be dedicated
to promote and develop consensus guidelines as practically as
possible in order to increase adherence.
Methylene blue and vasopressors have been described to
successfully restore refractory hypotension and recommended by
management guidelines (8), but their actual use in anaphylaxis
patients is scarce. There are multiple reports of successful
methylene blue use in refractory anaphylaxis (4). Evora (34)
reported 6 cases of refractory, perioperative anaphylaxis (to
RCM and penicillin) which responded to methylene blue i.v.
within minutes. Methylene blue blocks the guanylate cyclase and
therefore prevents further nitric-oxide-dependent vasodilation in
a distributive shock (35). Its potential role in neuroprotection has
also been indicated (36).
Surprisingly, even though multiple anaphylaxis management
guidelines recommend glucagon infusions in cases of
concomitant beta-blocker therapy in anaphylactic patients
(8, 37, 38), it has not been administered in any of the severe or
refractory cases. Similarly, Royal Collage of Anesthetists reported
one glucagon administration in 266 severe intraoperative
anaphylaxis episodes (39). Glucagon has been reported to
successfully relive refractory anaphylaxis (40, 41) by directly
activating the adenylyl cyclase and therefore bypassing the
β-adrenergic receptor blockade (40).
Limitations and Strengths
The low number of refractory cases prevented us from analyzing
the data with more advanced statistical models. However, our
analysis is the first report on a patient cohort exceeding 30
refractory anaphylaxis cases.
The definition of refractory anaphylaxis is not universal,
and we had to assume it based on the answers to our online
questionnaire. If a fatal reaction occurred before the second dose
of adrenaline was administered to the patient (although, it might
have been refractory)—it was not categorized as refractory as we
defined at least two doses of minimum 300 µg adrenaline for
refractory anaphylaxis.
The therapy with adrenaline was not weight-adapted, and
patients received multiple fixed doses of adrenaline ranging
from 300 to 1,000 µg. It is possible that patients experiencing
anaphylaxis refractory to standard doses of adrenaline were
treated with subtherapeutic doses in the initial phase of the
reaction due to their obesity. However, we did not gather data
on the patient’s weight, and therefore, we cannot conclude how it
influenced the therapy-outcomes with fixed doses of adrenaline.
Nevertheless, repeated doses of adrenaline should be sufficient to
alleviate the symptoms in such patients if the weight would be the
only reason for the refractoriness of anaphylaxis.
The comparison of refractory anaphylaxis with patients
suffering from severe anaphylaxis enabled us to distinguish
patients with a higher risk of developing a refractory episode.
However, we cannot address the question which patients had a
higher risk of experiencing anaphylaxis per se.
CONCLUSION
Refractory anaphylaxis is a rare form of a life-threatening
hypersensitivity reaction with high mortality. Its elicitors
and cofactors differ from other anaphylaxis cases, and the
management of refractory anaphylaxis needs to improve.
Although, more studies need to be conducted to understand
better the pathomechanisms involved in refractory anaphylaxis,
we propose to increase the use of second-line medication
such as methylene blue, vasopressin and (in suspicion of a
beta-adrenergic blockade) glucagon in cases where 2 doses
of adrenaline did not result in a rapid normalization of
anaphylaxis symptoms.
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